
Jim Gilligan, Interim CEO & Chief Scientific Officer of Tryp Therapeutics
by Nick Opich on June 16, 2022 in podcast
Podcast: Play in new window | Download
by Nick Opich on June 16, 2022 in podcast
Podcast: Play in new window | Download
Podcast: Play in new window | Download
This week on The Green Rush, Anne Donohoe and Sirita Wright are back with a new episode with guest Jim Gilligan, Interim Chief Executive Officer & Chief Scientific Officer of Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs.
Jim Gilligan Ph.D. has over 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs, and CMC manufacturing. Prior to joining Tryp, Jim helped lead multiple bio-pharma and biotech companies, including Tarsa Therapeutics, Herborium Inc., and Unigene Labs, where he was responsible for the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies. Jim received his Ph.D. in Pharmacology and Toxicology from the University of Connecticut and continued his post-graduate education at the Roche Institute of Molecular Biology
In this episode our hosts explore with Jim how Tryp is working to alleviate the suffering of patients with unmet diseases including, Fibromyalgia and binge eating disorders, the Company’s ongoing clinical trials, drug development pipeline, and what’s next in the psychedelic industry.
So sit back and enjoy our conversation with Jim Gilligan of Tryp Therapeutics
Links and mentions in the show
Links to the guest’s company and social media accounts
Show Credits:
This episode was hosted by Anne Donohoe and Sirita Wright of KCSA Strategic Communications.
Special thanks to our Program Director Shea Gunther and Producer Nick Opich.
You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:
Twitter: @The_GreenRush
Instagram: @thegreenrush_podcast
LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/
Facebook: https://www.facebook.com/TheGreenRushPodcast/
YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Kris Kane and Anne Donohoe return for a new episode with special guest Frank Perullo, Co-Founder and Strategic Advisor at Ascend Wellness Holdings ($AAWH). Frank joins us this week […]
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Lewis Goldberg and Anne Donohoe are back for a new episode with special guest Nathan Bryson, PhD, Chief Scientific Officer of Reunion Neuroscience. Nathan joins us this week to […]
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Anne Donohoe and Phil Carlson return for a new episode with special guest Len May, CEO and Co-Founder of Endocanna Health. Len joins us this week to share how […]
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Anne Donohoe and Kris Krane are back for a new episode with special guest Adam Smith, Founder of Alliance for Sensible Markets. Adam joined us this week to talk […]